These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30205983)

  • 1. Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.
    Brinkmann GH; Norvang V; Norli ES; Grøvle L; Haugen AJ; Lexberg ÅS; Rødevand E; Bakland G; Nygaard H; Krøll F; Widding-Hansen IJ; Bjørneboe O; Thunem C; Kvien T; Mjaavatten MD; Lie E
    Semin Arthritis Rheum; 2019 Apr; 48(5):808-814. PubMed ID: 30205983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
    Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.
    Steunebrink LM; Versteeg GA; Vonkeman HE; Ten Klooster PM; Kuper HH; Zijlstra TR; van Riel PL; van de Laar MA
    Arthritis Res Ther; 2016 Mar; 18():60. PubMed ID: 26956382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
    Vermeer M; Kievit W; Kuper HH; Braakman-Jansen LM; Bernelot Moens HJ; Zijlstra TR; den Broeder AA; van Riel PL; Fransen J; van de Laar MA
    BMC Musculoskelet Disord; 2013 Dec; 14():350. PubMed ID: 24330489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
    Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
    Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
    Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
    Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
    Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
    Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
    J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.
    Vermeer M; Kuper HH; Bernelot Moens HJ; Hoekstra M; Posthumus MD; van Riel PL; van de Laar MA
    Arthritis Res Ther; 2012 Nov; 14(6):R254. PubMed ID: 23176083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study.
    Brenol CV; da Chakr RM; Andrade NP; Toni M; Laurindo IM; Brenol JC; Xavier RM
    Clin Rheumatol; 2015 Oct; 34(10):1781-5. PubMed ID: 25771853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.
    Versteeg GA; Steunebrink LMM; Vonkeman HE; Ten Klooster PM; van der Bijl AE; van de Laar MAFJ
    Clin Rheumatol; 2018 May; 37(5):1189-1197. PubMed ID: 29388086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
    Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
    Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.